206 related articles for article (PubMed ID: 23192727)
1. MIA--a new target protein for malignant melanoma therapy.
Schmidt J; Riechers A; Bosserhoff AK
Histol Histopathol; 2013 Apr; 28(4):421-6. PubMed ID: 23192727
[TBL] [Abstract][Full Text] [Related]
2. Processing of MIA protein during melanoma cell migration.
Schmidt J; Bosserhoff AK
Int J Cancer; 2009 Oct; 125(7):1587-94. PubMed ID: 19521988
[TBL] [Abstract][Full Text] [Related]
3. Inducing anti-tumor cytokines and an immune response in melanoma by inhibition of MIA using the peptide AR71.
Riechers A; Schmidt J; Dettmer K; Oefner P; Jachimczak P; Schneider A; Bosserhoff AK
Eur J Dermatol; 2013; 23(6):820-5. PubMed ID: 24413571
[TBL] [Abstract][Full Text] [Related]
4. Cadherin-7 interacts with melanoma inhibitory activity protein and negatively modulates melanoma cell migration.
Winklmeier A; Contreras-Shannon V; Arndt S; Melle C; Bosserhoff AK
Cancer Sci; 2009 Feb; 100(2):261-8. PubMed ID: 19200257
[TBL] [Abstract][Full Text] [Related]
5. Targeting melanoma metastasis and immunosuppression with a new mode of melanoma inhibitory activity (MIA) protein inhibition.
Schmidt J; Riechers A; Stoll R; Amann T; Fink F; Spruss T; Gronwald W; König B; Hellerbrand C; Bosserhoff AK
PLoS One; 2012; 7(5):e37941. PubMed ID: 22666418
[TBL] [Abstract][Full Text] [Related]
6. Small Molecules Antagonise the MIA-Fibronectin Interaction in Malignant Melanoma.
Yip KT; Zhong XY; Seibel N; Pütz S; Autzen J; Gasper R; Hofmann E; Scherkenbeck J; Stoll R
Sci Rep; 2016 May; 6():25119. PubMed ID: 27151361
[TBL] [Abstract][Full Text] [Related]
7. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
[TBL] [Abstract][Full Text] [Related]
8. Migration-associated secretion of melanoma inhibitory activity at the cell rear is supported by KCa3.1 potassium channels.
Schmidt J; Friebel K; Schönherr R; Coppolino MG; Bosserhoff AK
Cell Res; 2010 Nov; 20(11):1224-38. PubMed ID: 20733613
[TBL] [Abstract][Full Text] [Related]
9. New drug targets in metastatic melanoma.
Homet B; Ribas A
J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of immunosuppressive effects of melanoma-inhibiting activity (MIA) by antisense techniques.
Jachimczak P; Apfel R; Bosserhoff AK; Fabel K; Hau P; Tschertner I; Wise P; Schlingensiepen KH; Schuler-Thurner B; Bogdahn U
Int J Cancer; 2005 Jan; 113(1):88-92. PubMed ID: 15386421
[TBL] [Abstract][Full Text] [Related]
11. Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma.
Bosserhoff AK; Dreau D; Hein R; Landthaler M; Holder WD; Buettner R
Recent Results Cancer Res; 2001; 158():158-68. PubMed ID: 11092043
[TBL] [Abstract][Full Text] [Related]
12. Advances in targeted therapy for unresectable melanoma: new drugs and combinations.
Hao M; Song F; Du X; Wang G; Yang Y; Chen K; Yang J
Cancer Lett; 2015 Apr; 359(1):1-8. PubMed ID: 25578781
[TBL] [Abstract][Full Text] [Related]
13. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
[TBL] [Abstract][Full Text] [Related]
14. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients.
Sanmamed MF; Fernández-Landázuri S; Rodríguez C; Lozano MD; Echeveste JI; Pérez Gracia JL; Alegre E; Carranza O; Zubiri L; Martín-Algarra S; González A
Clin Chim Acta; 2014 Feb; 429():168-74. PubMed ID: 24333389
[TBL] [Abstract][Full Text] [Related]
15. Functional role of melanoma inhibitory activity in regulating invasion and metastasis of malignant melanoma cells in vivo.
Bosserhoff AK; Echtenacher B; Hein R; Buettner R
Melanoma Res; 2001 Aug; 11(4):417-21. PubMed ID: 11479431
[TBL] [Abstract][Full Text] [Related]
16. Melanoma-inhibiting activity (MIA/CD-RAP) is expressed in a variety of malignant tumors of mainly neuroectodermal origin.
Hau P; Apfel R; Wiese P; Tschertner I; Blesch A; Bogdahn U
Anticancer Res; 2002; 22(2A):577-83. PubMed ID: 12014625
[TBL] [Abstract][Full Text] [Related]
17. Cloning and characterization of the expression pattern of a novel splice product MIA (splice) of malignant melanoma-derived growth-inhibiting activity (MIA/CD-RAP) [corrected].
Hau P; Wise P; Bosserhoff AK; Blesch A; Jachimczak P; Tschertner I; Bogdahn U; Apfel R
J Invest Dermatol; 2002 Sep; 119(3):562-9. PubMed ID: 12230496
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on pembrolizumab in the treatment of advanced melanoma.
Rajakulendran T; Adam DN
Drug Des Devel Ther; 2015; 9():2883-6. PubMed ID: 26082618
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of melanoma inhibitory activity (MIA) enhances extravasation and metastasis of A-mel 3 melanoma cells in vivo.
Guba M; Bosserhoff AK; Steinbauer M; Abels C; Anthuber M; Buettner R; Jauch KW
Br J Cancer; 2000 Nov; 83(9):1216-22. PubMed ID: 11027436
[TBL] [Abstract][Full Text] [Related]
20. Active detachment involves inhibition of cell-matrix contacts of malignant melanoma cells by secretion of melanoma inhibitory activity.
Bosserhoff AK; Stoll R; Sleeman JP; Bataille F; Buettner R; Holak TA
Lab Invest; 2003 Nov; 83(11):1583-94. PubMed ID: 14615412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
